Teva and Sanofi’s duvakitug clears key long-term hurdle in IBD race
Share
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
